Summary of PetVivo Holdings, Inc.

Business Overview

• Industry & Focus: PetVivo is an emerging biomedical device company specializing in manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals, primarily targeted at the veterinary market.

Core Products & Technologies

• Lead Product:
  • Spryng® with OsteoCushion® Technology: An intra-articular injectable device designed for dogs and horses to treat osteoarthritis and other joint afflictions.
  • Mimics natural cartilage using biocompatible particles made of collagen, elastin, and glycosaminoglycans like heparin.
  • Addresses the root causes of osteoarthritis, promoting joint tissue restoration and mechanical homeostasis.
• Market & Usage:
  • Targets osteoarthritis, a chronic degenerative joint disease affecting:
    • Dogs: Approximately 14 million affected.
    • Horses: Approximately 1 million affected.
  • The total U.S. market for pet care and products is about $123.6 billion (2021-2022), with vet care and product sales constituting about $34.3 billion.
  • The target market includes veterinary clinics and hospitals with few existing long-term solutions for osteoarthritis.

Commercialization & Distribution

• Started sales of Spryng® in Q2 FY2022.
• Distribution Agreements:
  • Initially had exclusive distribution with MWI (2022–2024), then shifted to non-exclusive, but mutually ended the agreement in March 2025.
  • Entered into agreements with Covetrus (2023–2025, ended February 2025).
  • Formed distribution partnerships with Vedco and Clipper (late 2024).
• Sales Channels:
  • Sold directly to veterinarians and through third-party distributors.
  • Customers are licensed veterinary practices.

Manufacturing

• Produces products in ISO 7 certified clean rooms in Minneapolis.
• Uses proprietary scalable self-assembly manufacturing processes.
• Planning to establish a second manufacturing facility later in 2025 to enhance capacity and supply chain resilience.

Product Pipeline & R&D

• Pipeline includes: 17 additional devices for veterinary and human applications.
• Focus on treatments for dermal fillers, cardiovascular devices, drug delivery systems, and orthopedic devices.
• Increasing efforts in clinical studies to expand distribution outlets and product applications.

Intellectual Property

• Portfolio includes 6 issued patents and 2 pending in the U.S., plus patents in Canada and the EU.
• Protects biomaterials, production processes, and product applications.
• Relies on trade secrets for manufacturing techniques and formulations.
• Owns trademarks for Spryng® and OsteoCushion®; common law rights in PetVivo™.

Market & Customers

• Approximately 258 shareholders as of March 31, 2025.
• Number of issued common stock shares: about 24.4 million (outstanding).
• Major customers include licensed veterinary practices, government agencies, and online purchasers (no specific customer count provided).

Financials

• 2025 Revenue: ~$1.13 million (up from ~$969k in 2024).
• Net Loss (2025): approximately $8.4 million (compared to ~$11 million in 2024).
• Operating expenses: Decreased to ~$9.05 million in 2025.
• Cash and equivalents: About $227,689 as of March 31, 2025.
• Recent financing: $5 million Series B Preferred stock offering, with part of the proceeds received.
• Losses: Significant, with an accumulated deficit of $91.2 million as of March 31, 2025.
• Employees: 24 as of July 10, 2025.

Regulatory & Clinical

• Spryng® classified as a veterinary medical device, not requiring pre-market approval in the U.S.
• Has completed studies including rabbit safety/efficacy, equine tolerance, and canine clinical trials.
• Planning and executing additional clinical studies for market expansion.

Summary

PetVivo specializes in innovative, biocompatible biomaterials for treating joint and tissue issues in animals, especially osteoarthritis in dogs and horses, with an expanding pipeline of products aimed at both veterinary and human medical markets. The company is actively commercializing Spryng® through various distribution channels, has multiple clinical trials supporting product safety and efficacy, owns significant intellectual property, and operates with a team of 24 employees. Financial losses continue, but recent funding efforts have provided working capital.